期刊
CELL
卷 184, 期 6, 页码 1575-1588出版社
CELL PRESS
DOI: 10.1016/j.cell.2021.02.011
关键词
-
资金
- American Cancer Society [MRAT-18-113-01]
- Melanoma Research Alliance [597698]
- NIH [R01 CA238039, R01CA251599, P01 CA163222, T32CA207021]
- NIH Mentored Clinical Scientist Development Award [1K08DK114563-01]
- American Gastroenterological Association Research Scholars Award
Immunotherapies have had a significant impact on cancer treatment over the past decade, but inflammatory toxicities remain a major concern for certain therapies. Understanding the balance between pro- and anti-inflammatory pathways is crucial for limiting inflammatory toxicities while preserving anti-tumor efficacy.
During the past decade, immunotherapies have made a major impact on the treatment of diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and Drug Administration (FDA)-approved checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies, but also limit the development and use of combination therapies. Fundamentally, these adverse events highlight the intricate balance of pro- and anti-inflammatory pathways that regulate protective immune responses. Here, we discuss the cellular and molecular mechanisms of inflammatory adverse events, current approaches to treatment, as well as opportunities for the design of immunotherapies that limit such inflammatory toxicities while preserving anti-tumor efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据